CEVEC raises € 4.5 million in a financing round to commercialize its leading CAP® based technologies

  • New and existing investors participated in this financing round
  • CEVEC is setting new industry standards in glyco-optimized protein and gene therapy vector production with proprietary CAP®Go and CAP®GT technologies

Cologne, Germany, July 22, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful completion of a financing round of € 4.5 million. New investors included Investtodate GmbH, Frank Ubags, CEO, and Nicole Faust, CSO of CEVEC. Existing investors also participated in this financing. These included Peppermint VenturePartners GmbH, Creathor Venture Management GmbH, NRW.Bank, KfW Bank, G.A.T. Holding as well as a number of private individuals.

READ MORE

CEVEC’s CAP®Go derived recombinant placental human alkaline phosphatase shows superior results in a preclinical study

  • New CAP®Go cell line for the production of glyco-optimized recombinant human alkaline phosphatase successfully established
  • CAP®Go derived recombinant human alkaline phosphatase optimized to address therapeutic needs in chronic inflammatory indications and neurodegenerative diseases

Cologne, Germany, July 06, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins, today announced the results of a preclinical animal study in which its CAP®Go derived recombinant placental human alkaline phosphatase (PLAP) showed significantly prolonged serum-half-life.

READ MORE

CEVEC grants license to Biotest AG for production of tailor-made glycoproteins

Cologne, Germany, July 1, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), an expert for the production of glyco-optimized biopharmaceuticals, today announced that it has granted a license for its proprietary CAP®Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients.

READ MORE

CEVEC INTRODUCES CAP®GO EXPRESSION SYSTEMS FOR SCALABLE PRODUCTION OF TAILOR-MADE GLYCOPROTEINS

Cologne, Germany, June 1, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, today announced the introduction of the technology platform CAP®Go for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® Technology.

READ MORE

CEVEC ANNOUNCES APPOINTMENT OF
LIFE SIENCES INDUSTRY EXPERT FRANK UBAGS
AS CHIEF EXECUTIVE OFFICER

Cologne, Germany, April 17, 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.

READ MORE

CEVEC: CAP® DERIVED RECOMBINANT C1 INHIBITOR MATCHES BERINERT® IN ANIMAL STUDY

Cologne, Germany, February 2, 2015

CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).
CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than …

READ MORE

CEVEC INTRODUCES CMO SERVICES
FOR THE cGMP MANUFACTURING OF CAP-BASED
CLINICAL MATERIALS

Cologne, Germany, September 23, 2014

CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.

READ MORE